martedì, 5 maggio 2026

Notizie AIOM – anno XVII

AUA Releases New Clinical Guideline for Diagnosis and Treatment of Early-Stage Testicular Cancer

May 16, 2019 - Recently, the American Urological Association (AUA) released a new clinical guideline on the diagnosis and treatment of early-stage testicular cancer. Testicular cancer is the most common cancer among men ages 20 to 40. Although it is a less common form of ...
Leggi tutto

EU Approves Lenalidomide- and Pomalidomide-Based Triplets for Myeloma

May 16, 2019 - The European Commission (EC) has granted an approval to lenalidomide in combination with bortezomib and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are ineligible for stem cell transplant, as well ...
Leggi tutto

16 maggio 2019 – Commissione Tecnico Scientifica (CTS)

16 maggio 2019 – Attivazione Registro Niraparib (Tesaro Bio)

FDA Panel Backs Pexidartinib for Tenosynovial Giant Cell Tumor

May 14, 2019 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 12 to 3 in favor of pexidartinib for an indication as a treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT). Under the Prescription Drug User Fee Act, the FDA will ...
Leggi tutto

FDA Panel Votes Against Quizartinib Approval for AML

May 14, 2019 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 8-3 against approving a new drug application (NDA) for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia (AML). The FDA is now scheduled to ...
Leggi tutto

FDA Approves Avelumab/Axitinib for Frontline RCC

May 15, 2019 - The FDA has approved the combination of avelumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma. The approval is based on results from the pivotal phase III JAVELIN Renal 101 trial, which showed that the combination ...
Leggi tutto

FDA Approves Venetoclax/Obinutuzumab Combo for Frontline CLL

May 15, 2019 - The FDA has approved the combination of venetoclax and obinutuzumab for the frontline treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The approval is based on findings from the phase III CLL14 trial, in which the ...
Leggi tutto

Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas

To investigate the trend in the launch price of new drugs for five common health conditions. Cross-sectional study using data on new drugs launched in the UK between 1981 and 2015 for hypertension, asthma, rheumatoid arthritis, schizophrenia and colorectal cancer. All drugs ...
Leggi tutto

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial (NCT01856296) navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing ...
Leggi tutto